Gossamer Bio (GOSS) Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GOSS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GOSS, but not buy additional shares or sell existing shares.
View GOSS analyst ratings or view top-rated stocks.

10 brokers have issued twelve-month price objectives for Gossamer Bio's shares. Their GOSS share price forecasts range from $1.50 to $17.00. On average, they expect the company's stock price to reach $7.32 in the next twelve months. This suggests a possible upside of 480.8% from the stock's current price.
View analysts price targets for GOSS or view top-rated stocks among Wall Street analysts.

Gossamer Bio's stock was trading at $2.17 at the start of the year. Since then, GOSS stock has decreased by 41.9% and is now trading at $1.26.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our GOSS earnings forecast.

Gossamer Bio, Inc. (NASDAQ:GOSS) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by $0.02. During the same period in the previous year, the company earned ($0.80) earnings per share.

WisdomTree BioRevolution Fund holds 2,078 shares of GOSS stock, representing 0.08% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Stoke Therapeutics (STOK), Precision BioSciences (DTIL) and Invitae (NVTA).

(GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

Gossamer Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.02%), Palo Alto Investors LP (3.63%), Platinum Investment Management Ltd. (2.48%), Acadian Asset Management LLC (2.32%), Two Sigma Investments LP (1.96%) and Two Sigma Advisers LP (1.93%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Luisa Salter-Cid, Richard Aranda and Waage Christian.
View institutional ownership trends.

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GOSS stock can currently be purchased for approximately $1.26.

Gossamer Bio (NASDAQ:GOSS) has a market capitalization of $120.25 million. The company earns $-229,380,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis.

The company employs 185 workers across the globe.

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The official website for the company is www.gossamerbio.com. The company can be reached via phone at (858) 684-1300 or via email at ir@gossamerbio.com.